Lyra Therapeutics reports FY2024 net loss $93.4M; ENLIGHTEN 2 top-line data expected Q2 2025

Lyra Therapeutics, Inc.

Net loss for FY2024 was $93.4M ($1.43 diluted EPS) vs $62.7M in FY2023; cash $40.6M as of Dec 31, 2024.
Top-line results from ENLIGHTEN 2 Phase 3 trial of LYR-210 in CRS expected in Q2 2025.
Positive post-hoc data from ENLIGHTEN 1 extension in polyp cohort; FDA alignment on registration path for CRSwNP.
Planned reverse stock split to maintain Nasdaq listing; requires shareholder approval in Q2 2025.
R&D expenses decreased to $43.8M from $48.0M due to trial completions and workforce reduction.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0000950170-25-038742
form_type: 8-K
ticker: LYRA
cik: 0001327273
company_name: Lyra Therapeutics, Inc.
filed_at: 2025-03-13T23:59:59+00:00
discovered_at: 2026-05-14T18:03:03.319799+00:00
generated_at: 2026-05-24T20:33:25.215883+00:00
sec_items: ["2.02", "9.01"]
event_type: other_material
sentiment: neutral
materiality_score: 0.65
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0000950170-25-038742
json_url: https://secwatch.observer/filing/0000950170-25-038742.json
markdown_url: https://secwatch.observer/filing/0000950170-25-038742.md
text_url: https://secwatch.observer/filing/0000950170-25-038742.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1327273/000095017025038742/0000950170-25-038742-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1327273/000095017025038742/lyra-20250313.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0000950170-25-038742

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.